TY - JOUR
T1 - Treatment of nontuberculous mycobacterial pulmonary disease
T2 - An official ATS/ERS/ESCMID/IDSA clinical practice guideline
AU - Daley, Charles L.
AU - Iaccarino, Jonathan M.
AU - Lange, Christoph
AU - Cambau, Emmanuelle
AU - Wallace, Richard J.
AU - Andrejak, Claire
AU - Böttger, Erik C.
AU - Brozek, Jan
AU - Griffith, David E.
AU - Guglielmetti, Lorenzo
AU - Huitt, Gwen A.
AU - Knight, Shandra L.
AU - Leitman, Philip
AU - Marras, Theodore K.
AU - Olivier, Kenneth N.
AU - Santin, Miguel
AU - Stout, Jason E.
AU - Tortoli, Enrico
AU - Van Ingen, Jakko
AU - Wagner, Dirk
AU - Winthrop, Kevin L.
N1 - Funding Information:
Conflict of interest: C.L. Daley served on advisory committees for Cipla, Horizon, Insmed, Johnson & Johnson, Matinas Biopharma, Otsuka America Pharmaceutical, Paratek, and Spero; received research support from Beyond Air, Insmed, and Spero; served as a consultant for Meiji. J.M. Iaccarino has nothing to disclose. C. Lange served as a speaker for Berlin Chemie, Chiesi, Gilead, Janssen, Lucane, and Novartis; served on an advisory committee for Oxford Immunotec. E. Cambau has nothing to disclose. R.J. Wallace Jr served as the director of a university clinical laboratory that does NTM identification, molecular strain comparison, and susceptibility testing; received research support from Insmed as mycobacterial reference laboratory for a trial of the inhaled liposomal amikacin. C. Andrejak received research support from Insmed. E.C. Böttger served as a consultant for AID Diagnostika, Becton Dickinson, and COPAN; provided expert testimony for Shuttleworth & Ingersoll law firm. J. Brozek has nothing to disclose. D.E. Griffith served on an advisory committee, as a consultant, as a speaker and received research support from Insmed; served as a consultant for Johnson & Johnson, Merck, and Spero. L. Guglielmetti has nothing to disclose. G.A. Huitt served on an advisory committee for Hill-Rom and Insmed. S.L. Knight has nothing to disclose. P. Leitman served as the president of NTM Info & Research, Inc, during which time the organization received support from Insmed, Grifols, BeyondAir, Aradigm, Spero Therapeutics, Johnson & Johnson, Hill-Rom, International Biophysics, Electromed, RespirTech, Maxor Specialty Pharmacy, PantherX, and Kroger Specialty Pharmacy. T.K. Marras served as a consultant and received research support from Insmed; served as a speaker for AstraZeneca and Novartis; served as a consultant for Horizon, Spero, and RedHill Biopharma. K.N. Olivier received research support from AIT Therapeutics, Insmed, and Matinas Biopharma. M. Santin received personal fees from DiaSorin SPA and Vircell SL. J.E. Stout has nothing to disclose. E. Tortoli has nothing to disclose. J. van Ingen served on an advisory committee and as a consultant for Insmed; served on advisory committees for Janssen Pharmaceuticals and Spero. D. Wagner served as a speaker for Cepheid GmbH; received research support and travel expenses from Insmed. K.L. Winthrop served on an advisory committee for Insmed, Johnson and Johnson, Paratek, Redhill Biopharma, and Spero; served as a consultant for Bayer Healthcare, Bristol-Myers Squibb, Horizon, Lilly, Pfizer, and RedHill Biopharma; received research support from Bristol-Myers Squibb, Cellestis, and Insmed; served on data safety and monitoring boards for Abbvie, Biomarin, Gilead, Roche, and UCB.
Funding Information:
C.L. Daley served on advisory committees for Cipla, Horizon, Insmed, Johnson & Johnson, Matinas Biopharma, Otsuka America Pharmaceutical, Paratek, and Spero; received research support from Beyond Air, Insmed, and Spero; served as a consultant for Meiji. J.M. Iaccarino has nothing to disclose. C. Lange served as a speaker for Berlin Chemie, Chiesi, Gilead, Janssen, Lucane, and Novartis; served on an advisory committee for Oxford Immunotec. E. Cambau has nothing to disclose. R.J. Wallace Jr served as the director of a university clinical laboratory that does NTM identification, molecular strain comparison, and susceptibility testing; received research support from Insmed as mycobacterial reference laboratory for a trial of the inhaled liposomal amikacin. C. Andrejak received research support from Insmed. E.C. B?ttger served as a consultant for AID Diagnostika, Becton Dickinson, and COPAN; provided expert testimony for Shuttleworth & Ingersoll law firm. J. Brozek has nothing to disclose. D.E. Griffith served on an advisory committee, as a consultant, as a speaker and received research support from Insmed; served as a consultant for Johnson & Johnson, Merck, and Spero. L. Guglielmetti has nothing to disclose. G.A. Huitt served on an advisory committee for Hill-Rom and Insmed. S.L. Knight has nothing to disclose. P. Leitman served as the president of NTM Info & Research, Inc, during which time the organization received support from Insmed, Grifols, BeyondAir, Aradigm, Spero Therapeutics, Johnson & Johnson, Hill-Rom, International Biophysics, Electromed, RespirTech, Maxor Specialty Pharmacy, PantherX, and Kroger Specialty Pharmacy. T.K. Marras served as a consultant and received research support from Insmed; served as a speaker for AstraZeneca and Novartis; served as a consultant for Horizon, Spero, and RedHill Biopharma. K.N. Olivier received research support from AIT Therapeutics, Insmed, and Matinas Biopharma. M. Santin received personal fees from DiaSorin SPA and Vircell SL. J.E. Stout has nothing to disclose. E. Tortoli has nothing to disclose. J. van Ingen served on an advisory committee and as a consultant for Insmed; served on advisory committees for Janssen Pharmaceuticals and Spero. D. Wagner served as a speaker for Cepheid GmbH; received research support and travel expenses from Insmed. K.L. Winthrop served on an advisory committee for Insmed, Johnson and Johnson, Paratek, Redhill Biopharma, and Spero; served as a consultant for Bayer Healthcare, Bristol-Myers Squibb, Horizon, Lilly, Pfizer, and RedHill Biopharma; received research support from Bristol-Myers Squibb, Cellestis, and Insmed; served on data safety and monitoring boards for Abbvie, Biomarin, Gilead, Roche, and UCB.
Publisher Copyright:
Copyright © 2020 The Author(s).
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.
AB - Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.
UR - http://www.scopus.com/inward/record.url?scp=85087721054&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087721054&partnerID=8YFLogxK
U2 - 10.1183/13993003.00535-2020
DO - 10.1183/13993003.00535-2020
M3 - Article
C2 - 32636299
AN - SCOPUS:85087721054
SN - 0903-1936
VL - 56
JO - The European respiratory journal
JF - The European respiratory journal
IS - 1
M1 - 2000535
ER -